{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:44:38Z","timestamp":1791571478476,"version":"4.3.4"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 105-2410-H-002-215"],"award-info":[{"award-number":["MOST 105-2410-H-002-215"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0220730","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T17:30:12Z","timestamp":1565976612000},"page":"e0220730","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status"],"prefix":"10.1371","volume":"14","author":[{"given":"Hsi-Chieh","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-3011","authenticated-orcid":true,"given":"Elise Chia-Hui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsien","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Zhe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"pone.0220730.ref001","unstructured":"American Cancer Society. Cancer facts and figures 2016: American Cancer Society; [cited 2017 Octorber 26]. Available from: http:\/\/www.cancer.org\/Research\/CancerFactsStatistics\/cancerfactsfigures2016\/cancerfactsandfigures2016."},{"key":"pone.0220730.ref002","unstructured":"American Cancer Society. What is non-small cell lung cancer? American Cancer Society [cited 2017 October 6]. Available from: http:\/\/www.cancer.org\/cancer\/lungcancer-non-smallcell\/detailedguide\/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer."},{"issue":"7","key":"pone.0220730.ref003","doi-asserted-by":"crossref","first-page":"740","DOI":"10.6004\/jnccn.2010.0056","article-title":"Non-small cell lung cancer","volume":"8","author":"DS Ettinger","year":"2010","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"issue":"1","key":"pone.0220730.ref004","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1378\/chest.128.1.452","article-title":"Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003","volume":"128","author":"P Yang","year":"2005","journal-title":"Chest"},{"key":"pone.0220730.ref005","doi-asserted-by":"crossref","first-page":"b375","DOI":"10.1136\/bmj.b375","article-title":"Prognosis and prognostic research: what, why, and how?","volume":"338","author":"KG Moons","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"pone.0220730.ref006","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/cncr.24151","article-title":"Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment","volume":"115","author":"MJ Park","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"pone.0220730.ref007","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JTO.0b013e318260e106","article-title":"Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab","volume":"7","author":"T Hoang","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"4","key":"pone.0220730.ref008","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ijrobp.2015.02.048","article-title":"A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients","volume":"92","author":"C Oberije","year":"2015","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"2","key":"pone.0220730.ref009","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ijc.28995","article-title":"Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests","volume":"136","author":"K Zhang","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"pone.0220730.ref010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2005.04.177","article-title":"Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data","volume":"23","author":"T Hoang","year":"2005","journal-title":"J Clin Oncol"},{"key":"pone.0220730.ref011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7150\/jca.2.52","article-title":"Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma","volume":"2","author":"CT Li","year":"2011","journal-title":"J Cancer"},{"issue":"6","key":"pone.0220730.ref012","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/cam4.689","article-title":"A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients","volume":"5","author":"H Mo","year":"2016","journal-title":"Cancer Med"},{"issue":"6","key":"pone.0220730.ref013","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JTO.0b013e3181729299","article-title":"National Cancer Institute of Canada Clinical Trials G. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21","volume":"3","author":"M Florescu","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"4","key":"pone.0220730.ref014","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4143\/crt.2013.120","article-title":"Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors","volume":"46","author":"B Keam","year":"2014","journal-title":"Cancer Res Treat"},{"issue":"12","key":"pone.0220730.ref015","first-page":"S400","article-title":"Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment","volume":"5","author":"S Kim","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"2","key":"pone.0220730.ref016","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"T Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"pone.0220730.ref017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"JC Yang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"pone.0220730.ref018","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"C Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"pone.0220730.ref019","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jfma.2019.01.012","article-title":"Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future","volume":"118","author":"CJ Chiang","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"pone.0220730.ref020","volume-title":"International Union against Cancer (UICC) TNM classification of malignant tumours","author":"LH GM Sobin","year":"2009","edition":"7th edition"},{"key":"pone.0220730.ref021","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001","volume-title":"Applied longitudinal data analysis [electronic resource]: modeling change and event occurrence","author":"JD Singer","year":"2003"},{"key":"pone.0220730.ref022","unstructured":"Tyler Smith, Besa Smith, Margaret AK Ryan. Survival Analysis Using Cox Proportional Hazards Modeling For Single And Multiple Event Time Data2003 [cited 2018 March 21]:[254\u201328 pp.]. Available from: http:\/\/www2.sas.com\/proceedings\/sugi28\/254-28.pdf."},{"key":"pone.0220730.ref023","volume-title":"Survival analysis using the SAS system: a practical guide","author":"Institute SAS","year":"1995"},{"key":"pone.0220730.ref024","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regresson Modelling Strategies: With applications to Linear Models, Logistic Regression, and Survival Analysis (Springer Series in Statistics)","author":"FE Harrell","year":"2001"},{"issue":"15","key":"pone.0220730.ref025","article-title":"Prognostic model in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy","volume":"29","author":"DZ Radosavljevic","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0220730.ref026","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1200\/JCO.2014.56.6661","article-title":"Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer","volume":"33","author":"W Liang","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0220730.ref027","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1097\/JTO.0000000000000691","article-title":"A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System","volume":"10","author":"J Lin","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"4","key":"pone.0220730.ref028","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JTO.0000000000000456","article-title":"Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry","volume":"10","author":"J Zhang","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"5","key":"pone.0220730.ref029","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cllc.2011.06.002","article-title":"Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms","volume":"12","author":"DP Carbone","year":"2011","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"pone.0220730.ref030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1183\/09031936.00010111","article-title":"Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma","volume":"39","author":"N Girard","year":"2012","journal-title":"The European respiratory journal"},{"issue":"6","key":"pone.0220730.ref031","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JTO.0b013e3181729299","article-title":"A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada clinical trials group study BR.21","volume":"3","author":"M Florescu","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"3","key":"pone.0220730.ref032","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2010.29.1609","article-title":"Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214","volume":"29","author":"EM Gore","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9804","key":"pone.0220730.ref033","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","article-title":"Non-small-cell lung cancer","volume":"378","author":"P Goldstraw","year":"2011","journal-title":"Lancet"},{"issue":"14","key":"pone.0220730.ref034","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2005.08.409","article-title":"Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer","volume":"23","author":"G Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0220730.ref035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2003.12.014","article-title":"Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, \"Iressa\") on an expanded access study","volume":"44","author":"PA Janne","year":"2004","journal-title":"Lung cancer"},{"issue":"6","key":"pone.0220730.ref036","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2","volume":"26","author":"R Lilenbaum","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0220730.ref037","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.2003.07.010","article-title":"Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer","volume":"21","author":"A Gajra","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0220730.ref038","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.athoracsur.2013.09.058","article-title":"Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer","volume":"97","author":"RU Osarogiagbon","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"pone.0220730.ref039","doi-asserted-by":"crossref","first-page":"e100994","DOI":"10.1371\/journal.pone.0100994","article-title":"Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer","volume":"9","author":"J Putila","year":"2014","journal-title":"PloS one"},{"issue":"8","key":"pone.0220730.ref040","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"A Iasonos","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0220730.ref041","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejca.2009.12.007","article-title":"The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation","volume":"46","author":"G Lughezzani","year":"2010","journal-title":"Eur J Cancer"},{"issue":"11","key":"pone.0220730.ref042","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"KY Bilimoria","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"pone.0220730.ref043","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2008.08.052","article-title":"Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy","volume":"74","author":"C Dehing-Oberije","year":"2009","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"2","key":"pone.0220730.ref044","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijrobp.2010.06.011","article-title":"Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325)","volume":"81","author":"C Dehing-Oberije","year":"2011","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"4","key":"pone.0220730.ref045","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JTO.0000000000000456","article-title":"Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer (NSCLC) An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry","volume":"10","author":"JJ Zhang","year":"2015","journal-title":"J Thorac Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0220730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:07:47Z","timestamp":1588964867000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0220730"}},"subtitle":[],"editor":[{"given":"Wan-Teck","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0220730","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]}}}